Keywords
Trigeminal neuralgia
Neuropathic pain
Facial pain
Botulinum toxin
Pharmacological treatment
How to Cite
Abstract
The Trigeminal Neuralgia (TN) is described as neuropathic pain at the orofacial level, characterized by unbearable pain that can last from a few seconds to several minutes. The different treatments used for these patients are to numb the nerve, surgical, pharmacological, and the administration at extra and intraoral level of botulinum toxin, which is a neurotoxin produced in cultures of the bacterium Clostridium botulinum in a natural way; in the sporulation process are 7 subtypes being the subtype A the most used in neurological problems. The botulinum toxin acts as a neuromuscular blocker, by inhibiting the release of acetylcholine at the synaptic space, which is an important neurotransmitter to produce local muscle relaxation, and the patients report reductions in the frequency and intensity of pain with minimal side effects. The injection of botulinum toxin produces an effective pain reduction of neuropathic origin in the hyperalgesic tissue and is used as adjuvant therapy when oral medications do not give adequate control of pain. Over time it is expected to reduce the drugs as the patient tells that the pain has decreased or is being controlled. Patients are indicated the variation of time in which they can obtain relief of their pain. In patients with uncontrolled pain of the trigeminal nerve, the toxin is placed extraoral in the orofacial region with high effectiveness, but there is a lack of studies on the administration in the intraoral submucosal.
References
Merskey H., Bogduk N. Classification of chronic pain: descriptors of chronic pain syndromes and definitions of pain terms, 2nd ed. Available at: www.iasp-pain.org/PublicationsNews/Content.aspx?ItemNumber=1673
Zakrzewska J. M., Linskey M. E. Trigeminal neuralgia. BMJ 2014; 348: g474.
Cruccu G., Gronseth G., Alksne J., Argoff C., Brainin M., Burchiel K., Nurmikko T., Zakrzewska J. M.; American Academy of Neurology Society; European Federation of Neurological Societies. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol 2008; 15: 1013-28.
Childs A. M., Meaney J. F., Ferrie C. D., Holland P. C. Neurovascular compression of the trigeminal and glossopharyngeal nerve: three case reports. Arch Dis Child 2000; 82: 311.
Katusic S., Williams D. B., Beard C. M., et al. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991; 10:276.
Katusic S., Beard C. M., Bergstralh E., Kurland L. T. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol 1990; 27: 89.
Maarbjerg S., Gozalov A., Olesen J., Bendtsen L. Trigeminal neuralgia--a prospective systematic study of clinical characteristics in 158 patients. Headache 2014; 54: 1574.
Fleetwood I. G., Innes A. M., Hansen S. R., Steinberg GK. Familial trigeminal neuralgia. Case report and review of the literature. J Neurosurg 2001; 95: 513.
Balasubramaniam, R. &Klasser, G. Orofacial pain syndromes, evaluation and management.MedClin N A. 2014; 98: 1385-1405.
Chumpitaz, V., Sayán, C., Ruíz, E., Franco, C., Herrera, E., Cueva, V., Castro, Y., y Erazo, C. Actualización de criterios diagnósticos y tratamiento de la neuralgia del trigémino. Odontología Sanmarquina. 2013; 16 (1): 44-48.
Dworkin R. H., O'Connor A. B., Backonja M., Farrar J. T., Finnerup N. B., Jensen T. S., Kalso E. A., Loeser J. D., Miaskowski C., Nurmikko T. J., Portenoy R. K., Rice A. S., Stacey B. R., Treede R. D., Turk D. C., Wallace M. S. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237-251.
Moulin D. E., Clark A. J., Gilron I., Ware M. A., Watson C. P., Sessle B. J., Coderre T., Morley-Forster P. K., Stinson J., Boulanger A., Peng P., Finley G. A., Taenzer P., Squire P., Dion D., Cholkan A., Gilani A., Gordon A., Henry J., Jovey R., Lynch M., MailisGagnon A., Panju A., Rollman G. B., Velly A., Canadian Pain Society. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007; 12: 13-21.
Attal N., Cruccu G., Haanpaa M., Hansson P., Jensen T. S., Nurmikko T., Sampaio C., Sindrup S., Wiffen P., EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13: 1153-1169.
Robaina, F. Neuralgia del Trigémino. Revisión del tratamiento médico y quirúrgico. Rev. Soc. Esp. Dolor. 2008; 4: 248-256.
Dworkin R. H., O'Connor A. B., Audette J., Baron R., Gourlay G. K., Haanpaa M. L., Kent J. L., Krane E. J., Lebel A. A., Levy R. M., Mackey S. C., Mayer J., Miaskowski C., Raja S. N., Rice A. S., Schmader K. E., Stacey B., Stanos S., Treede R. D., Turk D. C., Walco G. A., Wells C. D. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85: S3-14.
Zakrzewska J. M. Trigeminal neuralgia: unilateral episodic facial pain. J Pain Palliat Care Pharmacother 2015; 29: 182-184.
Zakrzewska J. M., Linskey M. E. Trigeminal neuralgia. BMJ Clin Evid 2014; 2014: 1207.
Finnerup N. B., Attal N., Haroutounian S., McNicol E., Baron R., Dworkin R. H., Gilron I., Haanpaa M., Hansson P., Jensen T. S., Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith B. H., Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015; 14: 162-173.
Padilla M., Clark G. T., Merrill R. L. Topical medications for orofacial neuropathic pain: a review. J Am Dent Assoc 2000; 131: 184-195.
Nasri-Heir C., Khan J., Heir G. M. Topical medications as treatment of neuropathic orofacial pain. Dent Clin North Am 2013; 57: 541-553.
Zuniga C., Piedimonte F., Diaz S., Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol 2013; 36: 146-150.
K. R. Aoki, B. Guyer. Botulinum toxin type A and other botulinum toxin serotypes: A comparative review of biochemical and pharmacological actions. Eur J Neurol, 8 (Suppl 5) (2001), pp. 21-29.
S. Aurora. Botulinum toxin type A for the treatment of migraine. Expert Opin Pharmacother, 7 (2006), pp. 1085-1095.
S. O. Mittal, D. Safarpour, B. Jabbari. Botulinum toxin treatment of neuropathic pain. Semin Neurol., 36 (2016), pp. 73-83.
S. Mense. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol, 251 (Suppl 1) (2004), pp. I1-I7.
G. Verma. Role of botulinum toxin type-A (BTX-A) in the management of trigeminal neuralgia. Pain Res Treat., 2013 (2013), p. 831094.
Aoki K. R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005; 26: 785-793.
Oh H. M., Chung M. E. Botulinum Toxin for Neuropathic Pain: A Review of the Literature. Toxins (Basel) 2015; 7: 3127-3154.
Federico Castillo-Álvarez, Ignacio Hernando de la Bárcena, María Eugenia Marzo-Sola. Botulinum toxin in trigeminal neuralgia. Medicina Clínica (English Edition), Volume 148, Issue 1, 6 January 2017, Pages 28-32.
Filho R. R., Zimmermann G. S., Gonçalves B. M. Applications of Botulinum Toxin in Dentistry - Literature Review. J Dent Oral Biol. 2016; 1 (3): 1013.
Hu Y., Guan X., Fan L., Li M., Liao Y., Nie Z., Jin L. Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J Headache Pain 2013; 14: 72-2377-14-72.
Babiloni A. H., Kapos F. P., Nixdorf D. R. Intraoral Administration of Botulinum Toxin for Trigeminal Neuropathic Pain. Oral Med Oral Pathol Oral Radiol. 2016; 121: e148-e153.
Kowacs P. A., Utiumi M. A., Nascimento F. A., Piovesan E. J., Teive H. A. Onabotulinumtoxin A for trigeminal neuralgia: a review of the available data. Arq Neuropsiquiatr 2015; 73: 877-884.
Micheli F., Scorticati M. C., Raina G. Beneficial effects of botulinum toxin type A for patients with painful tic convulsif. Clin Neuropharmacol 2002; 25: 260-262.
Borodic G. E., Acquadro M. A. The use of botulinum toxin for the treatment of chronic facial pain. J Pain 2002; 3: 21-27.
Felicio A. C., Godeiro C. de O.,Jr., Borges V., Silva S. M., Ferraz H. B. Bilateral hemifacial spasm and trigeminal neuralgia: a unique form of painful tic convulsif. Mov Disord 2007; 22: 285-286.
Bosca-Blasco M. E., Burguera-Hernandez J. A., Roig-Morata S., Martinez-Torres I. Painful tic convulsif and Botulinum toxin. Rev Neurol 2006; 42: 729-732.
Volcy M., Tepper S. J., Rapoport A. M., Sheftell F. D., Bigal M. E. Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: a case report with pathophysiological considerations. Cephalalgia 2006; 26: 336-340.
Ngeow W. C., Nair R. Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109: e47-50.
Uluduz D., Karaali-Savrun F., Gunduz A., Kiziltan M. E. An unusual case of vascular loop syndrome. J Headache Pain 2007; 8: 242-244.
Fabregat G., De Andres J., Villanueva-Perez V. L., Asensio-Samper J. M. Subcutaneous and perineural botulinum toxin type A for neuropathic pain: a descriptive review. Clin J Pain 2013; 29: 1006-1012.
Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA 2011; 305: 89-90.
Li S., Lian Y. J., Chen Y., Zhang H. F., Ma Y. Q., He C. H., Wu C. J., Xie N. C., Zheng Y. K., Zhang Y. Therapeutic effect of Botulinum toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up. J Headache Pain 2014; 15: 43-2377-15-43.
Bohluli B., Motamedi M. H., Bagheri S. C., Bayat M., Lassemi E., Navi F., Moharamnejad N. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 111: 47-50.
Allam N., Brasil-Neto J. P., Brown G., Tomaz C. Injections of botulinum toxin type a produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain 2005; 21: 182-184.
Turk U., Ilhan S., Alp R., Sur H. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol 2005; 28: 161-162.
Walker T. J., Dayan S. H. Comparison and overview of currently available neurotoxins. J. Clin Aesthet Dermatol 2014; 7: 31-39.
Kim A., Jung J., Pak A. Botulinum toxin type A reconstituted in lidocaine with epinephrine for facial rejuvenation: results of a participant satisfaction survey. Cutis 2013; Suppl: 13-18.
Gassner H. G., Sherris D. A. Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study. Mayo Clin Proc 2000; 75: 701-704.
Vadoud-Seyedi J., Simonart T. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br J Dermatol 2007; 156: 986-989.